Biocon’s S&P Global ESG Score improves to 69 for 2024
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring
700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
Mesalazine is used to treat inflammatory bowel disease
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Subscribe To Our Newsletter & Stay Updated